PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes-Reference-Cited by-同舟云学术

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes

Published:2015-11-16 Issue:3 Volume:41 Page:374-383
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Mega Jessica L.,Close Sandra L.,Wiviott Stephen D.,Man Michael,Duvvuru Suman,Walker Joseph R.,Sundseth Scott S.,Collet Jean-Philippe,Delaney Jessica T.,Hulot Jean-Sebastien,Murphy Sabina A.,Paré Guillaume,Price Matthew J.,Sibbing Dirk,Simon Tabassome,Trenk Dietmar,Antman Elliott M.,Sabatine Marc S.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-015-1264-9.pdf

Reference35 articles.

1. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189

2. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

3. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908–2913

4. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362. doi: 10.1056/NEJMoa0809171

5. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375. doi: 10.1056/NEJMoa0808227

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular pharmacogenomics – Molecular basis of protective and adverse drug response;Genomic and Molecular Cardiovascular Medicine;2024

2. Advances and Perspectives in methods for identifying high platelet reactivity;Heliyon;2023-12

3. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk;Genes;2023-11-09

4. Association between Q192R PON1 genetic polymorphism and major adverse cardiovascular events in patients treated with clopidogrel: an updated meta-analysis;Expert Opinion on Drug Safety;2023-05-08

5. Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention;Pharmacogenomics;2023-03